These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy. Hu S; Huang KM; Adams EJ; Loprinzi CL; Lustberg MB Clin Cancer Res; 2019 Nov; 25(21):6295-6301. PubMed ID: 31123053 [TBL] [Abstract][Full Text] [Related]
6. High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies. Rossignol J; Cozzi B; Liebaert F; Hatton S; Viallard ML; Hermine O; Greco C Support Care Cancer; 2019 Aug; 27(8):3053-3059. PubMed ID: 30607681 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Ewertz M; Qvortrup C; Eckhoff L Acta Oncol; 2015 May; 54(5):587-91. PubMed ID: 25751757 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological and Nonpharmacological Management of Chemotherapy-Induced Peripheral Neuropathy: A Scoping Review of Randomized Controlled Trials. Jones KF; Wechsler S; Zulewski D; Wood L J Palliat Med; 2022 Jun; 25(6):964-995. PubMed ID: 35128938 [No Abstract] [Full Text] [Related]
9. Therapeutic strategies for cancer treatment related peripheral neuropathies. Pachman DR; Watson JC; Loprinzi CL Curr Treat Options Oncol; 2014 Dec; 15(4):567-80. PubMed ID: 25119581 [TBL] [Abstract][Full Text] [Related]
10. Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy. Bakogeorgos M; Georgoulias V Expert Rev Anticancer Ther; 2017 Nov; 17(11):1045-1060. PubMed ID: 28868935 [TBL] [Abstract][Full Text] [Related]
11. Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists' professional practices. Selvy M; Pereira B; Kerckhove N; Busserolles J; Farsi F; Guastella V; Merle P; Pezet D; Balayssac D Support Care Cancer; 2021 Jul; 29(7):4033-4043. PubMed ID: 33403401 [TBL] [Abstract][Full Text] [Related]
13. Prevention and treatment of chemotherapy-induced peripheral neuropathy. Piccolo J; Kolesar JM Am J Health Syst Pharm; 2014 Jan; 71(1):19-25. PubMed ID: 24352178 [TBL] [Abstract][Full Text] [Related]
14. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. Flatters SJL; Dougherty PM; Colvin LA Br J Anaesth; 2017 Oct; 119(4):737-749. PubMed ID: 29121279 [TBL] [Abstract][Full Text] [Related]
15. Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial. Clavo B; Martínez-Sánchez G; Rodríguez-Esparragón F; Rodríguez-Abreu D; Galván S; Aguiar-Bujanda D; Díaz-Garrido JA; Cañas S; Torres-Mata LB; Fabelo H; Téllez T; Santana-Rodríguez N; Fernández-Pérez L; Marrero-Callico G Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802143 [TBL] [Abstract][Full Text] [Related]
16. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Kuriyama A; Endo K Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005 [TBL] [Abstract][Full Text] [Related]
17. Melittin, a honeybee venom derived peptide for the treatment of chemotherapy-induced peripheral neuropathy. Tender T; Rahangdale RR; Balireddy S; Nampoothiri M; Sharma KK; Raghu Chandrashekar H Med Oncol; 2021 Apr; 38(5):52. PubMed ID: 33796975 [TBL] [Abstract][Full Text] [Related]